What is FRC's Proprietary Fair Value Model?

FRC's Proprietary Fair Value Model is a premium feature that provides access to the same valuation methodology used by Fundamental Research Corp for allocating our firm's capital. This institutional-grade model combines fundamental analysis, financial modeling, and market metrics to determine a stock's intrinsic value. The model analyzes financial statements, earnings quality, growth rates, profitability ratios, and comparative valuations to calculate data-driven fair value estimates that professional investors trust for investment decisions. Available to premium subscribers.

What is Kamada Ltd. stock price today?

Kamada Ltd. (KMDA) is currently trading at $7.06 USD on NASDAQ. Get real-time price updates, Snowflake performance analysis, and comprehensive financial statements. Premium subscribers can access fair value analysis using FRC's proprietary valuation model.

What does Kamada Ltd. do?

Kamada Ltd. operates in the Drug Manufacturers - Specialty & Generic sector within Healthcare. Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its...

How do I analyze Kamada Ltd. stock performance?

Our Snowflake Analysis provides a visual snapshot of Kamada Ltd. performance across 5 key metrics: Past Performance, Revenue Growth, Profitability, Value, and Financial Health. Each metric is scored 1-5, with 5 being excellent performance. This multi-dimensional view helps investors quickly assess stock quality and compare performance against peers.

Where can I find Kamada Ltd. financial statements?

Access Kamada Ltd. complete financial statements including income statement, balance sheet, and cash flow statement in our comprehensive stock profile. Our platform provides detailed financial ratios, trend analysis, and institutional-grade financial analysis used by professional investors.

What makes FRC's stock analysis different from other platforms?

FRC uses the same proprietary valuation model for public stock analysis that we use for allocating our own firm's capital. This means our fair value estimates are based on the same rigorous, data-driven methodology that institutional investors trust. Our analysis includes real-time pricing, Snowflake performance metrics, comprehensive financial modeling, and research reports from professional analysts - providing institutional-grade insights for individual investors.

About Kamada Ltd.

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

CEO

Amir London

Headquarters

2 Holzman Street, Rehovot, IL

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

CEO

Amir London

Headquarters

2 Holzman Street, Rehovot, IL

Description

Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Kamada Ltd.

KMDA•NASDAQ

Kamada Ltd.

KMDA•NASDAQ

Market cap

$407.32M

Sentiment

Your view on KMDA

Mkt Cap

$407.32M

Sentiment

Your view

Company Overview

Overview

What the company does, where it operates, and who runs it.

About Kamada Ltd.

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
CEO: Amir London
Headquarters: 2 Holzman Street, Rehovot, IL

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
CEO: Amir London
Headquarters: 2 Holzman Street, Rehovot, IL

Description

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News